CHOLESTASIS TREATMENT MARKET ANALYSIS

Market Trends

One of the major cholestasis types is obstetric cholestasis. According to the Royal College of Obstetricians and Gynecologists, obstetric cholestasis affects 0.7% of pregnancies in the multiethnic populations in addition to 1.2–1.5% of pregnant women of Indian or Pakistani origin in England. The prevalence of obstetric cholestasis is shaped by genetic as well as environmental factors. The statistics vary amongst populations worldwide. For instance, 2.4% of all pregnancies are affected in Chile. There is growing prevalence of this disease in the world, which in turn will propel the growth of the overall cholestasis treatment market.

Cholestasis disease can affect many aspects of lipid metabolism. Accumulation of toxic bile constituents in hepatocytes owing to disturbance of bile flow from the liver to the gut can harm hepatocytes, which might result in damaged synthetic functionality and lessened production of enzymes concerned in lipoprotein metabolism. Moreover, lipoprotein discharge is disturbed at some stage during cholestasis, revealed by a decline in HDL levels and the emergence of the abnormal lipoprotein X in the plasma. Since cholestasis can be linked to a variety of diseases, its treatment is of utmost importance. Technological advancements as well as development of efficient diagnostic tests will ensure early detection of the disease, thereby augmenting growth of the cholestasis treatment market.

Growing prevalence of obstetric cholestasis to drive growth of the overall cholestasis treatment market

According to a report published in the National Center for Biotechnology Information, intrahepatic cholestasis of pregnancy (ICP) or obstetric cholestasis is the major liver disease during pregnancy. Obstetric cholestasis is characteristically a reversible disease typically occurring in the second to third trimester. It is characterized by pruritus (severe itching of the skin) mainly in the palms and soles, prominent serum aminotransferases coupled with increased serum bile acid levels. As the number of pregnancies is likely to increase in the near future, so is the prevalence of cholestasis. Moreover, cholestasis can be hereditary in nature. There is a significant presence of chronic cholestasis in children owing to the nature of the disease. According to the National Center for Biotechnology Information, hereditary disorders of biliary atresia and intrahepatic cholestasis are the major causes of chronic liver disease amongst children. In children, they also act as the key indicators for liver transplantation. The growing population ensures increased occurrences of the disease amongst children. This in turn will drive growth of the overall cholestasis treatment market during the forecast period.